Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02734277 · ClinicalTrials.gov registry record
Type 1 Diabetes Extension Study
A clinical trial of Type 1 Diabetes Mellitus and T1D, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 111
- Enrollment target
- 12
- Study locations
NCT02734277 is a study of Type 1 Diabetes Mellitus and T1D that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 111 participants, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (20% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT02734277, a study of Type 1 Diabetes Mellitus and T1D, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
Conditions Studied
Study Locations (12)
California
- UCSF School of Medicine - San Francisco
- Stanford University - Stanford
Colorado
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes - Aurora
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Indiana
- Indiana University Riley Hospital for Children - Indianapolis
Iowa
- University of Iowa Health Care Division of Pediatric Endocrinology - Iowa City
Massachusetts
- Joslin Diabetes Center - Boston
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2016-08-18 |
| Est. Completion | 2028-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02734277
The ClinicalTrials.gov registry entry for NCT02734277 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (20% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.
NCT02734277 reports 12 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02734277 about?
NCT02734277 is a clinical study titled "Type 1 Diabetes Extension Study". This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how lon...
What is the current status of trial NCT02734277?
This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2016-08-18. Estimated completion is 2028-08.
What conditions does trial NCT02734277 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, T1D, T1DM.
Who is sponsoring clinical trial NCT02734277?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02734277 being conducted?
This trial has 12 study locations across California, Colorado, Connecticut, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.